



## **Rocket Doctor AI Completes Acquisition of Alea Health to Expand Access to Therapist-Led Mental Health Care**

- *Rocket Doctor AI has completed the acquisition of Alea Health, strengthening its AI-powered digital health platform and accelerating the delivery of physician-led care.*
- *The acquisition supports Rocket Doctor AI's mission to improve access to high-quality healthcare, particularly for underserved and remote communities across Canada and the United States.*
- *This milestone reflects the Company's continued execution on its growth strategy, integrating complementary technology to enhance clinical efficiency, care consistency, and patient outcomes.*

**Vancouver, British Columbia, January 8, 2026 – Rocket Doctor AI Inc. (the “Company” or “Rocket Doctor AI”) (CSE: AIDR, OTC: AIRDF, Frankfurt: 939)** is pleased to announce, further to its news releases dated January 28, 2025 and November 19, 2025, that it has closed its previously announced acquisition (the “Transaction”) of Alea Health Holdings Ltd. (“Alea”) pursuant to the terms of a definitive share purchase agreement dated November 19, 2025, as amended on December 31, 2025 (the “Definitive Agreement”), among the Company, Alea, and the ordinary shareholders of Alea (the “Alea Shareholders”).

The acquisition of Alea strengthens Rocket Doctor AI's technology portfolio by adding complementary capabilities that enhance clinical workflows, data-driven decision support, and the delivery of consistent, high-quality care across digital healthcare environments.

“This acquisition represents an important step forward in executing our strategy to build a scalable, physician-led digital health ecosystem,” said Dr. Essam Hamza, Chief Executive Officer of Rocket Doctor AI. “Alea brings technology and domain expertise that align closely with our Global Library of Medicine and broader platform vision. Together, we are better positioned to support clinicians, improve care consistency, and expand access to high-quality healthcare for patients across North America, including underserved and remote communities.”

Following the closing of the Transaction, Alea's team and technology will be integrated into Rocket Doctor AI's platform and product roadmap. The Company plans to incorporate Alea's capabilities into its broader AI and digital health ecosystem, supporting ongoing development of tools that enhance clinical decision-making, streamline workflows, and improve consistency and quality of care delivery across its physician-led marketplace.

“Joining Rocket Doctor AI allows Alea's technology to scale within a broader clinical and operational framework that is deeply aligned with our original mission,” said Richard Dallala, Founder and Chief Executive Officer of Alea Health. “We're excited to see our work integrated into a platform that prioritizes physician leadership, evidence-based care, and meaningful improvements in patient outcomes.”



## Transaction Overview

Pursuant to the terms of the Definitive Agreement, the Company acquired 100% of the issued and outstanding ordinary shares in the capital of Alea by making the following payments:

- (i) a cash payment of US \$15,000, which was previously paid as an acquisition deposit; and
- (ii) the issuance of 285,712 common shares (each, a "Consideration Share") in the capital of the Company on the closing date, issued pro rata to the Alea Shareholders, with a deemed value of CAD \$0.70 per Consideration Share.

The Company has also agreed to assume and satisfy Alea's obligations under a Simple Agreement for Future Equity (the "SAFE Note") by paying the US \$180,000 principal balance of the SAFE Note in equal monthly installments of US \$22,500 per month (each, an "Installment") until paid in full. The first Installment under the SAFE Note was paid concurrently with the closing of the Transaction.

All securities issued pursuant to the Transaction were issued under prospectus exemptions in accordance with National Instrument 45-106 – *Prospectus Exemptions* and are subject to an applicable statutory hold period of four months and one day from the date of issuance. The Consideration Shares are also subject to a 28-month contractual escrow release schedule, whereby 20% of the Consideration Shares are released from escrow every four months, beginning on the first anniversary of the closing date of the Transaction.

Alea and its shareholders are arm's length parties to the Company. No finder's fees were paid in connection with the Transaction. The Company has not assumed any long-term liabilities of Alea, other than the SAFE Note.

## About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company's proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc's products and services, contact:



[www.rocketdoctor.ai](http://www.rocketdoctor.ai) or email: [info@rocketdoctor.ai](mailto:info@rocketdoctor.ai)

**FOR ADDITIONAL INFORMATION, CONTACT:**

Dr. Essam Hamza, CEO, Rocket Doctor AI [essam.hamza@rocketdoctor.ai](mailto:essam.hamza@rocketdoctor.ai)

For media inquiries, contact: [media@rocketdoctor.ai](mailto:media@rocketdoctor.ai)

Call: +1 (778) 819 8321

**Cautionary Statements**

*This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Proposed Transaction, closing of the Proposed Transaction as anticipated or at all, and receipt of all regulatory approvals and satisfaction of all conditions precedent to closing of the Proposed Transaction., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is*

*cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward- looking statements as expressly required by Canadian securities law.*